MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Opko Health Company Profile (NYSE:OPK)

Consensus Ratings for Opko Health (NYSE:OPK) (?)
Ratings Breakdown: 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $16.33 (112.12% upside)

Analysts' Ratings History for Opko Health (NYSE:OPK)
Show:
DateFirmActionRatingPrice TargetActions
10/16/2015JPMorgan Chase & Co.Initiated CoverageOverweight$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/28/2015Barrington ResearchReiterated RatingBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/11/2015Jefferies GroupDowngradeBuy -> Hold$10.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2015Ladenburg ThalmannReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015LaidlawInitiated CoverageBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2015OppenheimerDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2015Barrington ResearchReiterated RatingOutperform$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/26/2015Barrington ResearchInitiated CoverageOutperform$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015OppenheimerDowngradeOutperform -> Market Perform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2014OppenheimerReiterated RatingPositive$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2014Jefferies GroupReiterated RatingBuy$11.00 -> $10.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2014Jefferies GroupReiterated RatingBuy$11.50 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2014OppenheimerLower Price TargetOutperform$13.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2014Ned Davis ResearchUpgradeSell -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/13/2014OppenheimerInitiated CoverageOutperform$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/9/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha